Clinical Cancer Research, Vol 3, Issue 9 1491-1500, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice

S Visonneau, A Cesano, MH Torosian and D Santoli
The Wistar Institute, and The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

Although enormous progress has been made in the detection and treatment of localized (nonmetastatic) breast cancer, there has been relatively moderate progress toward the effective treatment of advanced disease. This study investigates the antitumor efficacy of a potent MHC nonrestricted cytotoxic human T cell line (TALL-104) upon transfer into a clinically relevant mouse model of metastatic breast cancer. Fragments from a surgical specimen of a patient with infiltrating ductal carcinoma were implanted s.c. in the flank region of severe combined immunodeficient (SCID) mice. One hundred % of the animals developed a local tumor mass that metastasized to subaxillary and inguinal lymph nodes, bones, lungs, liver, kidneys, ovaries, and brain, very closely mimicking the human disease. Multiple i.p. transfers of gamma-irradiated (nonproliferating) TALL-104 cells into mice bearing low tumor burden (the primary tumor mass weighed only 150 mg) completely arrested local tumor growth and prevented systemic spread into local lymph nodes and distant organs. Remarkably, cell therapy administered in an advanced disease stage (when the tumor weighed 2 g) induced a significant or total regression of established metastasis with no obvious effects on the primary tumor mass. Profound antitumor effects against both local and systemic disease were instead seen in mice that received cell therapy after surgical excision of the primary tumor. The implications of these data in adjuvant breast cancer therapy are discussed.

This article has been cited by other articles:

				C. Brando, S. Mukhopadhyay, E. Kovacs, R. Medina, P. Patel, T. L. Catina, K. S. Campbell, and D. Santoli Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104 J. Leukoc. Biol., August 1, 2005; 78(2): 359 - 371. [Abstract] [Full Text] [PDF]

				M. F. Kircher, J. R. Allport, E. E. Graves, V. Love, L. Josephson, A. H. Lichtman, and R. Weissleder In Vivo High Resolution Three-Dimensional Imaging of Antigen-Specific Cytotoxic T-Lymphocyte Trafficking to Tumors Cancer Res., October 15, 2003; 63(20): 6838 - 6846. [Abstract] [Full Text] [PDF]

				M. A. Chung, Y. Luo, M. O'Donnell, C. Rodriguez, W. Heber, S. Sharma, and H. R. Chang Development and Preclinical Evaluation of a Bacillus Calmette-Guerin-MUC1-based Novel Breast Cancer Vaccine Cancer Res., March 15, 2003; 63(6): 1280 - 1287. [Abstract] [Full Text] [PDF]

				C. A. Kruse, S. Visonneau, B. K. Kleinschmidt-DeMasters, C. J. Gup, G. G. Gomez, D. B. Paul, and D. Santoli The Human Leukemic T-Cell Line, TALL-104, Is Cytotoxic to Human Malignant Brain Tumors and Traffics through Brain Tissue: Implications for Local Adoptive Immunotherapy Cancer Res., October 1, 2000; 60(20): 5731 - 5739. [Abstract] [Full Text]

				S. Visonneau, A. Cesano, D. L. Porter, S. L. Luger, L. Schuchter, M. Kamoun, M. H. Torosian, K. Duffy, C. Sickles, E. A. Stadtmauer, et al. Phase I Trial of TALL-104 Cells in Patients with Refractory Metastatic Breast Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1744 - 1754. [Abstract] [Full Text]

				B. Geoerger, C.-B. Tang, A. Cesano, S. Visonneau, S. Marwaha, K. D. Judy, L. N. Sutton, D. Santoli, and P. C. Phillips Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts Neuro-oncol, April 1, 2000; 2(2): 103 - 113. [Abstract] [PDF]

				S. Visonneau, A. Cesano, K. A. Jeglum, and D. Santoli Adjuvant Treatment of Canine Osteosarcoma with the Human Cytotoxic T-Cell Line TALL-104 Clin. Cancer Res., July 1, 1999; 5(7): 1868 - 1875. [Abstract] [Full Text] [PDF]

				T. Guillaume, D. B. Rubinstein, and M. Symann Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation Blood, September 1, 1998; 92(5): 1471 - 1490. [Full Text] [PDF]